1. Depemokimab showed significant efficacy in reducing nasal polyp scores and obstruction symptoms in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). 
2. The agent offers a reduced dosing schedule compared to existing biologics for CRSwNP.
3. Researchers reported a significant reduction in total endoscopic nasal polyps score and improved Sino-Nasal Outcome Test 22 scores among patients receiving depemokimab.
4. Fewer patients taking depemokimab required systemic corticosteroids or surgery for CRSwNP.
5. Safety outcomes were comparable between treatment groups.

Source: The Lancet